approval
saveSKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
community read0 votes
Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 198d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 18, 2026 · 198d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 210d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 6, 2026 · 210d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 394d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalSep 3, 2025 · 394d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 513d ago
- approvalSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMay 7, 2025 · 513d ago
same company · ±60 days · 6
- approvalrisankizumab: SKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalMar 4, 2024
- approvalESCITALOPRAM OXALATE — FDA approvalMar 8, 2024
- approvalIMBRUVICA (IBRUTINIB) — FDA approvalFeb 22, 2024
- approvaldivalproex sodium DR: DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvalMar 18, 2024
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMar 18, 2024
- approvaldivalproex sodium DR: DEPAKOTE (DIVALPROEX SODIUM) — FDA approvalMar 18, 2024
comments(0)
5-min edit window · permanent after that